GlaxoSmithKline said Monday that a Phase 2 trial of its COVID-19 vaccine, developed with French partner Sanofi, showed a "strong neutralizing antibody response" in adult participates of all age groups and raised no safety issues. "We believe that this vaccine candidate can make a significant contribution to the ongoing fight against COVID-19 and will move to Phase 3 as soon as possible to meet our goal of making it available before the end of the year," said Roger Connor, president of GSK's vaccines program.
The Phase 3 trial, expected to start in the next few weeks, is slated to involve 35,000 adults from a number of countries. The vaccine is based on Sanofi's seasonal flu vaccine, combined with an immunity-boosting adjuvant from GSK. The companies had hoped to seek regulatory approval in the first half of 2021, but pushed back those plans after disappointing results in December. The favorable new findings will help GSK CEO Emma Walmsley stave off pressure from activist investor Elliott Management, which took a large stake in GSK in April, The Guardian reports.
Subscribe to The Week
Escape your echo chamber. Get the facts behind the news, plus analysis from multiple perspectives.
Sign up for The Week's Free Newsletters
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
From our morning news briefing to a weekly Good News Newsletter, get the best of The Week delivered directly to your inbox.
-
Why Turkey's Kurdish insurgents are laying down their armsUnder the Radar The PKK said its aims can now be 'resolved through democratic politics'
-
Book reviews: 'Girl on Girl: How Pop Culture Turned a Generation of Women Against Themselves' and 'Notes to John'Feature The aughts' toxic pop culture and Joan Didion's most private pages
-
The FDA plans to embrace AI agencywideIn the Spotlight Rumors are swirling about a bespoke AI chatbot being developed for the FDA by OpenAI
-
Trump seeks to cut drug prices via executive orderspeed read The president's order tells pharmaceutical companies to lower prescription drug prices, but it will likely be thrown out by the courts
-
RFK Jr.: A new plan for sabotaging vaccinesFeature The Health Secretary announced changes to vaccine testing and asks Americans to 'do your own research'
-
RFK Jr. visits Texas as 2nd child dies from measlesSpeed Read An outbreak of the vaccine-preventable disease continues to grow following a decade of no recorded US measles deaths
-
Shingles vaccine cuts dementia risk, study findsSpeed Read Getting vaccinated appears to significantly reduce the chances of developing Alzheimer's and other forms of dementia
-
Measles outbreak spreads, as does RFK Jr.'s influenceSpeed Read The outbreak centered in Texas has grown to at least three states and Health Secretary Robert F. Kennedy Jr. is promoting unproven treatments
-
Five years on: How Covid changed everythingFeature We seem to have collectively forgotten Covid’s horrors, but they have completely reshaped politics
-
RFK Jr. offers alternative remedies as measles spreadsSpeed Read Health secretary Robert F. Kennedy Jr. makes unsupported claims about containing the spread as vaccine skepticism grows
-
Texas outbreak brings 1st US measles death since 2015Speed read The outbreak is concentrated in a 'close-knit, undervaccinated' Mennonite community in rural Gaines County
